<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615664</url>
  </required_header>
  <id_info>
    <org_study_id>PLRG-HL1</org_study_id>
    <nct_id>NCT03615664</nct_id>
  </id_info>
  <brief_title>The Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD Therapy</brief_title>
  <acronym>BURGUND</acronym>
  <official_title>The Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD Therapy- Multicentre Phase II Clinical Study (PLRG-HL1/BURGUND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Lymphoma Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polish Lymphoma Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is evaluation of efficacy of Bendamustine, Gemcytabine,
      Dexamethasone (BGD) salvage therapy with autologus stem cell transplantation (ASCT)
      consolidation in advanced classical Hodgkin lymphoma patients not responding to ABVD therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment regimen:

      Bendamustine (B) 90 mg/m2 iv day 1, 2 Gemcytabine (G) 800 mg/m2 iv day 1, 4 Dexamethasone (D)
      40 mg iv/po day 1,2,3,4

      Course of treatment every 21-28 days, 4 courses of treatment max; next round of treatment may
      be given if ANC&gt;1000/μl and PLT&gt;75000/μl. Up to 7-day delay is permitted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">May 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR (overall response rate)</measure>
    <time_frame>Evaluated at the end of Cycle 2 of BGD (every cycle is 21-28 days)</time_frame>
    <description>CR (complete response) + PR (partial response)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS (progression-free survival)</measure>
    <time_frame>Time measured from date of of Cycle 2 of BGD treatment (every cycle is 21-28 days) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Staying free of disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>Time measured from Day 1 of Cycle 1 of BGD treatment (every cycle is 21-28 days) until the date of death from any cause, assessed up to 24 months (measured for patients that have undergone ASCT after BGD tratment).</time_frame>
    <description>The length of time from the start of treatment, that patients diagnosed with the disease are still alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMRR (overall metabolic response rate)</measure>
    <time_frame>Evaluated a the end of Cycle 2 of BGD treatment (every cycle is 21-28 days) and after ASCT (up to 150 days after Day 1 of Cycle 1 of BGD treatment).</time_frame>
    <description>OMRR= CMR (complete metabolic response) + PMR (partial metabolic response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BGD tolerability assessment.</measure>
    <time_frame>24 months from the start of BGD treatment</time_frame>
    <description>Number of participants with treatment-related adverse events and serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR (mobilization rate)</measure>
    <time_frame>Evaluated after the end of Cycle 2 of BGD (every cycle is 21-28 days), before tranplantation (up to Day 150 of treatment).</time_frame>
    <description>Evaluation of stem cells mobilization efficacy in patients on BGD regimen.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>BGD therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine, Gemcitabine, Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine (B) 90 mg/m2 i.v. day 1, 2</description>
    <arm_group_label>BGD therapy</arm_group_label>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine (G) 800 mg/m2 i.v. day 1, 4</description>
    <arm_group_label>BGD therapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4</description>
    <arm_group_label>BGD therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:
in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment
in case of SMD - exclusion from the trial
in case of PMD - exclusion from the trial</description>
    <arm_group_label>BGD therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplant</intervention_name>
    <description>Must be performed within 3 months after the end of BGD treatment.
When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT.</description>
    <arm_group_label>BGD therapy</arm_group_label>
    <other_name>ASCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Classical Hodgkin's Lymphoma treated with ABVD regimen with
             PET scan/CT performed before, during and after treatment, and also one of the
             following:

               -  positive result (Deauville 4 and 5) of early PET scan after 2 ABVD courses

               -  disease progression or relapse after first-line ABVD treatment or ABVD and
                  radiotherapy combination treatment

          -  No contraindications for salvage chemotherapy and ASCT

          -  At least one measurable malignancy

          -  ECOG performance status ≤ 3

          -  Written signed and dated informed consent prior to any study procedures being
             performed

        Exclusion Criteria:

          -  Non-Classical Hodgkin's Lymphoma

          -  Other than ABVD first-line treatment, preceding patient's inclusion

          -  Lack of PET scans performed in accordance with inclusin criteria during ABVD treatment

          -  Transformation of Hodgkin's Lymphoma

          -  Central Nervous System (CNS) Metastases

          -  Contraindications for ASCT or lack of patient's consens for the procedure

          -  Second malignancy - active or cured less than 5 years prior

          -  Uncontrolled diabetes

          -  Hepatic impairment (bilirubin concentration ≥ 1.5 x ULN, SGOT &gt; 5 x ULN), if
             non-realted to the lymphoma or Gilbert's syndrome

          -  HIV infection

          -  Active HBV or HCV infection. Subjects who have had Hepatitis B and are abHBC positive,
             need to undergo HBV DNA test using a Polymerase Chain Reaction (PCR) technique and be
             applied appropriate preventive treatment.

          -  Pregnancy or lactation

          -  Hypersensitivity to any of the drugs

          -  Lack of written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Giebel, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>PLRG's Chairman</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan M Zaucha, Prof.</last_name>
    <phone>699 84 38</phone>
    <phone_ext>+48 58</phone_ext>
    <email>jzaucha@gumed.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Walewski, Prof.</last_name>
    <phone>546 22 23</phone>
    <phone_ext>+48 22</phone_ext>
    <email>walewski@coi.waw.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oddział Kliniczny Onkologii, Centrum Onkologii im. Prof. F. Łukaszczyka</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Chmielowska, PhD</last_name>
      <email>ewacelin@poczta.wprost.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michał Taszner, PhD</last_name>
      <email>mtaszner@uck.gda.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Sp. z o.o.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Knopińska-Posłuszny, PhD</last_name>
      <email>wanda.knopinska@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie, Oddział w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <zip>44-102</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Najda, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Chorób Wewnętrznych i Chemioterapii Onkologicznej, Samodzielny Publiczny Szpital Kliniczny im. A.Mielęckiego</name>
      <address>
        <city>Katowice</city>
        <zip>40-027</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grzegorz Helbig, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Hematologii, Szpital Specjalistyczny im. Rydygiera</name>
      <address>
        <city>Kraków</city>
        <zip>30-001</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Małgorzata Raźny, PhD</last_name>
      <email>m.razny@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematoonkologii i Transplantacji Szpiku, Samodzielny Publiczny Szpital Kliniczny nr 1</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Hus, Prof.</last_name>
      <email>iwonach.hus@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Hematologii, Samodzielny Publiczny ZOZ MSWiA z Warmińsko-Mazurskim Centrum Onkologii</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janusz Hałka, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Hematologii i Onkologii Hematologicznej, Szpital Wojewódzki w Opolu</name>
      <address>
        <city>Opole</city>
        <zip>45-372</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Woszczyk, PhD</last_name>
      <email>dariuszwoszczyk@o2.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NU-MED Centrum Diagnostyki i Terapii Onkologicznej</name>
      <address>
        <city>Tomaszów Mazowiecki</city>
        <zip>97-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Chmielowska, PhD</last_name>
      <email>ewacelin@poczta.wprost.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. M. Skłodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Paszkiewicz-Kozik, PhD</last_name>
      <email>epaszkiewicz@coi.waw.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Chorób Wewnętrznych i Hematologii, Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edyta Subocz, PhD</last_name>
      <email>suboczka@poczta.onet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1</name>
      <address>
        <city>Wrocław</city>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Wróbel, Prof.</last_name>
      <email>tomasz_wrobel@wp.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Immunochemotherapy</keyword>
  <keyword>Salvage therapy</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Hodgkin's Lymphoma</keyword>
  <keyword>ASCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

